On April 26, 2026, Sun Pharmaceutical Industries – India’s largest pharmaceutical manufacturer announced that it has entered into a definitive agreement to acquire US-based Organon & Co. The transaction will be an all-cash deal valued at approximately $11.75 billion.
This landmark transaction marks the largest overseas acquisition ever undertaken by an Indian pharmaceutical company. It signals that Sun Pharma is rapidly transitioning from a company focused primarily on generic drugs to becoming a global leader in speciality healthcare.
Sun Pharma: Key Financial Details of This Deal
A) Offer Price: Sun Pharma will pay $14.00 in cash for each share. This price represents a significant premium (exceeding 100% compared to unaffected trading prices at the beginning of the month).
B) Funding: The acquisition will be funded through a combination of Sun Pharma’s existing cash reserves and committed financing secured from banks. Timeline: The deal is expected to close in early 2027, subject to approval from Organon’s shareholders and regulatory bodies across the globe.
Strategic Impact of This Deal
The acquisition of Organon, which was spun off from Merck (MSD) in 2021, will fundamentally transform Sun Pharma’s global profile:
A) Women’s Health Powerhouse: Sun Pharma will immediately join the ranks of the top three companies globally in the women’s health sector. It will gain a portfolio of over 70 products focused on reproductive health, contraception (such as Nexplanon), and menopause.
B) Entry into the Biosimilars Market: This deal provides a “plug-and-play” easy and direct entry point into the rapidly expanding biosimilars market. Sun Pharma will now rank as the 7th largest biosimilars manufacturer globally.
C) Geographical Reach: This deal will significantly reduce Sun Pharma’s reliance on the US and Indian markets, as its operations will expand on a massive scale across China and the European Union. The newly formed entity will operate in over 150 countries.
D) Scale and Revenue: Following the completion of the deal, Sun Pharma’s revenue is projected to double, reaching approximately $12.4 billion.
Summary Table: Post-Acquisition Status
| Metric | Post-Acquisition Status |
| Global Ranking | Top 25 Pharma Company |
| Combined Revenue | ~$12.4 Billion |
| Women’s Health | Top 3 Global Player |
| Biosimilars | 7th Largest Globally |
| Market Reach | 150+ Countries (Strong China/EU presence) |
Additionally, it will be included in the list of the world’s top 25 pharmaceutical companies. Sun Pharma Chairman Dilip Shanghvi said, “We avoid borrowing, but we never hesitate to take risks.” He stressed that although this deal has a lot of debt involved, immediate access to biosimilar and women’s health platforms was a strategic necessity, one that would have taken many years if we had built it alone from the beginning.
Also Read: India’s Top 5 IT Companies Face AI Reset After Mixed FY26 Results
